Brookline Capital Markets Starts Dermata Therapeutics In (DRMA) at Buy

September 21, 2021 10:28 AM EDT
Get Alerts DRMA Hot Sheet
Price: $4.54 +3.18%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 48
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Dermata Therapeutics In (NASDAQ: DRMA) with a Buy rating and a price target of $14.00.

Analyst says: "We foresee a favorable risk reward as DMT310 and DMT410 advance through the clinic as there is significant unmet medical need for skin diseases and aesthetics. Key risks include cash position, expected to fund operations through late 2022, and dependence on harvested sponge."

For an analyst ratings summary and ratings history on Dermata Therapeutics In click here. For more ratings news on Dermata Therapeutics In click here.

Shares of Dermata Therapeutics In closed at $4.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage